Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine
暂无分享,去创建一个
R. Yelensky | J. O’Shaughnessy | J. Pippen | G. Palmer | S. Balasubramanian | N. Palma | B. Brooks | J. Blum | Kai Wang | N. Hoke | Corinne Ramos | M. Levin | Ying Cao | J. Ross
[1] J. Desterro,et al. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint , 2014, eLife.
[2] M. Meyerson,et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. , 2014, The Journal of clinical investigation.
[3] S. Millis,et al. Abstract PD4-1: Comparison of mutations and protein expression in potentially actionable targets in 5500 triple negative vs. non-triple negative breast cancers , 2013 .
[4] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[5] P. Fasching,et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Escargueil,et al. ATP-dependent chromatin remodeling and histone acetyltransferases in 5-FU cytotoxicity in Saccharomyces cerevisiae. , 2013, Genetics and molecular research : GMR.
[7] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[8] C. Sander,et al. Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.
[9] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[10] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[11] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[12] D. Mavroudis,et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. , 2012 .
[13] V. Georgoulias,et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] N. Robert,et al. Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. , 2012, The oncologist.
[15] Doron Lipson,et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.
[16] F. Bertucci,et al. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. , 2010, Anticancer research.
[17] A. Escargueil,et al. DNA repair pathways involved in repair of lesions induced by 5-fluorouracil and its active metabolite FdUMP. , 2010, Biochemical pharmacology.
[18] P Kelly Marcom,et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S. Culine,et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. , 2004, European journal of cancer.
[20] A. Buzdar,et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Winship. Interest. , 1893 .
[22] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .